Topic: Identifying the latest development & innovation approach for effective signal management   Bill is a biotech safety professional with more than 13 years’ experience in the industry with expertise in pediatrics, public health, epidemiology, and benefit-risk management.  He is Head of Safety at Ovid Therapeutics, a small biotech focused on therapeutics for neurologic conditions. Previously, he was at Biogen as Global Safety Lead for Tysabri.  Prior to this he was a Global Safety Officer at Amgen for 10 years in roles of increasing responsibility leading teams across multiple therapeutic areas including nephrology (Aranesp, Epogen Velcalcetide), heart failure (Aranesp, Omecamtiv), and oncology products (Denosumab, Neulasta, Neupogen).     Prior to this role he was a Clinical Instructor at the UCLA Department of Pediatrics and had a role with the LA County Public Health Department leading quality improvement projects. Bill completed his MD from Emory University, his MPH from the Harvard School of Public health, and his MS in Health Services from UCLA.  He completed his internship in Pediatrics at the University of North Carolina followed by a Preventive Medicine and Public Health residency at SUNY-Stony Brook.